Inhibrx Biosciences INBX
NASDAQ INBX
$98.74 +3.44 (+3.61%)
As of: Oct 21, 2026 · 12:59 PM EDT

Inhibrx Biosciences (INBX) Total Debt (2023 - 2026)

Updated

Inhibrx Biosciences' Total Debt came in at $176.29 million for Q2 2026, up 77.6% from $99.28 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) Total Debt (2023 - 2026) Analysis & Trends

At the end of FY2025, Inhibrx Biosciences' Total Debt was $100.56 million.

  • Going back by year, Total Debt was $206.97 million in FY2023.
  • The Q2 2026 figure represents the highest quarterly Total Debt since Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,134.62 Bn 1,103.20 Bn 19.71 Bn 54.91 Bn
2 Johnson & Johnson 616.94 Bn 535.47 Bn 17.26 Bn 49.04 Bn
3 AbbVie 501.32 Bn 474.43 Bn 12.70 Bn 70.82 Bn
4 Merck 367.44 Bn 321.82 Bn 12.21 Bn 53.91 Bn
5 Novartis Ag 298.20 Bn 262.19 Bn 11.24 Bn 9.59 Bn
6 Astrazeneca 261.78 Bn 235.47 Bn 12.86 Bn 32.35 Bn
7 Amgen 235.70 Bn 191.10 Bn 7.24 Bn 57.30 Bn
8 Gilead Sciences 190.88 Bn 165.07 Bn 6.22 Bn 26.25 Bn
9 Pfizer 169.72 Bn 116.36 Bn 10.94 Bn 63.19 Bn
10 Inhibrx Biosciences 1.54 Bn 942.91 Mn - 176.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 176.29 Mn
Dec 31, 2025 100.56 Mn
Sep 30, 2025 99.92 Mn
Jun 30, 2025 99.28 Mn
Mar 31, 2025 98.65 Mn
Dec 31, 2023 206.97 Mn
API Access

Inhibrx Biosciences Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=INBX&period=max&api_key=YOUR_API_KEY